<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Adjuvant paclitaxel and trastuzumab for small, node-negative, HER2-positive breast cancer&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Adjuvant paclitaxel and trastuzumab for small, node-negative, HER2-positive breast cancer<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Adjuvant paclitaxel and trastuzumab for small, node-negative, HER2-positive breast cancer<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> Paclitaxel and trastuzumab weekly for 12 weeks; trastuzumab monotherapy every 3 weeks for 40 weeks (13 cycles).<br/> <strong>Duration of therapy:</strong> One year or until disease progression or unacceptable toxicity. </td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Trastuzumab*</td> <td>Loading dose: 4 mg/kg IV<sup>¶</sup></td> <td>Dilute in 250 mL NS<sup>Δ</sup> and administer over 90 minutes for the loading dose. <strong>Do not</strong> mix with D5W and <strong>do not</strong> infuse as an IV push or bolus.</td> <td>Day 1 only</td> </tr> <tr> <td>Trastuzumab*</td> <td>2 mg/kg IV<sup>¶</sup><sup>◊</sup></td> <td>Dilute in 250 mL NS<sup>Δ</sup> and administer over 30 minutes for subsequent doses. <strong>Do not</strong> mix with D5W and <strong>do not</strong> infuse as an IV push or bolus.</td> <td>Day 8 then weekly for 11 weeks</td> </tr> <tr> <td>Paclitaxel<sup>§</sup></td> <td>80 mg/m<sup>2</sup> IV<sup>¶</sup></td> <td>Dilute in 250 mL NS<sup>Δ</sup> and administer over one hour (final concentration range, 0.3 to 1.2 mg/mL); special tubing is needed.<sup>¥</sup><sup>[2]</sup> Administer trastuzumab prior to paclitaxel when given concomitantly.</td> <td>Day 1 then weekly for 12 weeks total (12 doses)</td> </tr> <tr class="divider_bottom"> <td>Trastuzumab*</td> <td>6 mg/kg IV<sup>¶</sup></td> <td>Dilute in 250 mL NS<sup>Δ</sup> and administer over 30 minutes for subsequent doses. <strong>Do not</strong> mix with D5W and <strong>do not</strong> infuse as an IV push or bolus.</td> <td>Every 3 weeks starting after week 12 for 13 doses</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>LOW. </li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration. Continue dexamethasone and H1 receptor antagonist for the first two doses; may drop in subsequent cycles if no hypersensitivity reactions. Most clinicians do not routinely premedicate prior to the first trastuzumab dose. However, patients may be instructed to self-administer acetaminophen or an NSAID if flu-like symptoms develop within 24 hours of trastuzumab administration. </li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy and infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiopulmonary issues</strong></td> <td colspan="3"> <ul> <li>Trastuzumab is associated with cardiotoxicity; assess baseline LVEF prior to therapy and then at least every 3 months during therapy. Patients with baseline LVEF &lt;50% were excluded from this study.<sup>[1]</sup> Trastuzumab may cause serious pulmonary toxicity and should be used with caution in patients with preexisting pulmonary disease.<sup>[3]</sup> </li> <li>Refer to UpToDate topics on cardiotoxicity of trastuzumab and other HER2-targeted agents and pulmonary toxicity associated with antineoplastic therapy, molecularly targeted agents. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Paclitaxel is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Primary prophylaxis with G-CSF is not indicated; however, G-CSF was permitted during weekly paclitaxel for secondary prophylaxis.<sup>[1]</sup> </li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>A lower starting dose of paclitaxel may be needed in patients with liver impairment. </li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents. </li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Obtain CBC with differential and platelet count prior to each administration of paclitaxel. </li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess electrolytes and liver and renal function prior to each administration of paclitaxel. </li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for infusion reactions, especially during the first two courses of trastuzumab. </li> <li>Refer to UpToDate topics on infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy. </li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess cardiac function at baseline and 3, 6, and 12 months after starting trastuzumab.<sup>[1]</sup> </li> <li>Refer to UpToDate topics on cardiotoxicity of trastuzumab and other HER2-targeted agents. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Assess changes in neurologic function prior to each dose of paclitaxel. </li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Weekly paclitaxel should only be administered if the ANC is &gt;800/microL and platelets are ≥100,000/microL.<sup>[1]</sup> If the ANC is &lt;800/microL or platelets are &lt;100,000/microL, delay paclitaxel until count recovery and administer trastuzumab. </li> <li>No dosage adjustments for hematologic toxicity are recommended for this protocol except for febrile neutropenia.<sup>[1]</sup> For the second and subsequent episodes of febrile neutropenia, reduce remaining doses by 10 mg/m<sup>2</sup>. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Hepatotoxicity</strong></td> <td colspan="3"> <ul> <li>For grade 2 elevations in total bilirubin, transaminases, and/or ALP during therapy, hold paclitaxel for one week, and if the abnormal tests improve to grade 1 or 0, continue paclitaxel at full dose.<sup>[1]</sup> If the elevations remain at grade 2, continue paclitaxel at 70 mg/m<sup>2</sup>, and if they subsequently return to grade 0 or 1, return to full dose, 80 mg/m<sup>2</sup>. Patients should permanently discontinue treatment if grade 3 or 4 toxicity occurs.<sup>[1]</sup> </li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neurotoxicity</strong></td> <td colspan="3"> <ul> <li>No paclitaxel dose modifications are required for grade 1 or 2 neurotoxicity.<sup>[1]</sup> For grade 3 neurotoxicity, delay paclitaxel until toxicity has resolved to ≤grade 2, and reduce subsequent doses by 10 mg/m<sup>2</sup> if resolution to ≤grade 2 within 2 weeks. If resolution requires &gt;2 weeks or grade 4 neurotoxicity is reached, patient should discontinue treatment. If grade 3 neurotoxicity develops with additional infusions, further dose reductions may be made in increments of 10 mg/m<sup>2</sup>. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiotoxicity</strong></td> <td colspan="3"> <ul> <li>Guidelines for managing trastuzumab in patients with symptomatic or asymptomatic cardiac dysfunction during therapy are available.<sup>[1]</sup> </li> <li>Refer to UpToDate topics on cardiotoxicity of trastuzumab and other HER2-targeted agents. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Pulmonary toxicity</strong></td> <td colspan="3"> <ul> <li>Discontinue trastuzumab for serious pulmonary toxicity. </li> <li>Refer to UpToDate topics on pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents. </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infusion reactions</strong></td> <td colspan="3"> <ul> <li>Respond as clinically indicated with supportive care and possible discontinuation of therapy for severe reactions. </li> <li>Refer to UpToDate topics on infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other grade 3 or 4 toxicity</strong></td> <td colspan="3"> <ul> <li><strong>For most other grade 3 or 4 toxicities (diarrhea, mucositis), delay treatment until toxicity resolves to grade 1 or 0, then resume treatment with a reduced dose of paclitaxel.</strong> Recommendations for paclitaxel dose reduction or discontinuation are available.<sup>[1]</sup> </li> <li><strong>Trastuzumab: No dose modifications are permitted. If paclitaxel is delayed for any reason other than cardiotoxicity or severe hypersensitivity reactions that occurred when both paclitaxel and trastuzumab were administered, trastuzumab may be continued.</strong> </li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">HER2: human epidermal growth factor receptor 2; IV: intravenous; NS: normal saline; D5W: 5% dextrose in water; NSAID: nonsteroidal anti-inflammatory drug; LVEF: left ventricular ejection fraction; G-CSF: granulocyte-colony stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count; ALP: alkaline phosphatase; IHC: immunohistochemical; FISH: fluorescence in situ hybridization.<br/>
* High levels of HER2 overexpression, as determined by either 3+ IHC staining or positive FISH, are used to select patients for therapy with trastuzumab and pertuzumab. Refer to UpToDate topic on "HER2 and predicting response to therapy in breast cancer".<br/>
¶ Doses calculated with actual body weight only are recommended for this treatment protocol.<sup>[1]</sup><br/>
Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/>
<span class="lozenge">◊</span> The US Prescribing Information for trastuzumab suggests administration of a reloading dose for delays of more than one week during the weekly component of adjuvant therapy. Administration of such dose is per provider's discretion.<sup>[3]</sup><br/>
§ Adjuvant hormonal therapy is recommended for women with hormone receptor-positive tumors after the completion of paclitaxel therapy.<sup>[1]</sup><br/>
§ Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 and 1.2 mg/mL.<br/>
¥ Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-line administration sets with a microporous membrane 0.22 microns or less.</div><div class="graphic_reference">References:
<ol>
<li>Tolaney SM, et al. N Engl J Med 2015; 372:134.</li>
<li>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">www.dailymed.nlm.nih.gov</a>, accessed on June 22, 2017).</li>
<li>Herceptin (trastuzumab) injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">www.dailymed.nlm.nih.gov</a>, accessed on June 22, 2017).</li>
</ol></div><div id="graphicVersion">Graphic 119872 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
